Das könnte Sie auch interessieren:

"Die Geissens" werden in den Adelsstand gehoben

München (ots) - "Die Geissens" zwischen Obertauern und Paris - Neue Doppelfolge über Deutschlands wohl ...

Was die PR-Elite besser macht als der Durchschnitt: Exzellenz in der Unternehmenskommunikation

Hamburg (ots) - Was unterscheidet einen durchschnittlichen von einem herausragenden Kommunikationsprofi? Vier ...

Big Bang zum Abschluss: Wer gewinnt das Finale der ProSieben-Show "Masters of Dance"?

Unterföhring (ots) - Wer gewinnt die ProSieben-Show "Masters of Dance"? Im großen Finale am Donnerstag, 10. ...

27.11.2000 – 15:48

CryoLife, Inc.

CryoLife, Inc. Declares A 3-For-2 Stock Split

    Atlanta (ots-PRNewswire) - CryoLife, Inc. (NYSE: CRY), the leader in  the development and commercialization of living human tissue implantable  devices and a manufacturer of stentless heart valves and surgical adhesives, announced that its Board of Directors has authorized a 3-for-2 stock split, to  be effected as a stock dividend, to shareholders of record on December 8, 2000. New share certificates will be mailed to shareholders on December 27, 2000. Fractional shares will be aggregated and sold, with the proceeds distributed to shareholders in lieu of the issuance of such shares. CryoLife, Inc. had approximately 12,500,000 common shares outstanding as of November 27, 2000.

    Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc. noted, "The action of the Board of Directors follows the recent increase in  the Company's share price and provides an opportunity to increase the  liquidity of the Company. The availability of additional shares should also  enable future investors to trade more actively in the company's stock".

    Founded in 1984, CryoLife, Inc. is the leader in the development and  commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United  States and Canada. The Company's BioGlue(R) Surgical Adhesive is approved as  an adjunct in the repair of acute thoracic aortic dissections under HDE  regulations in the United States and is CE marked in the European Union and  approved in Canada for use in vascular and pulmonary sealing and repair. The  Company also manufactures the SynerGraft(R) heart valve, the world's first tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and  CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for  distribution within the European Community.  

    For additional information about the company, visit CryoLife's web site:  http://www.cryolife.com .  

ots Original Text Service: CryoLife, Inc. Internet: http://recherche.newsaktuell.de

Contact: Roy Vogeltanz, Vice President, Corporate Communications, of CryoLife, Inc., 800-438-8285

Web site: http://www.cryolife.com

Original-Content von: CryoLife, Inc., übermittelt durch news aktuell

Alle Meldungen
Abonnieren Sie alle Meldungen von CryoLife, Inc.
  • Druckversion
  • PDF-Version

Themen in dieser Meldung